Dr. Reddy's eyes aspirational goal to be in top five in the Indian market

Live Events
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
Pharma major Dr Reddy's Laboratories Ltd is increasingly focussing on launching innovative products through partnerships with an aim to grow at 15-16% in India, a top company official said.'We look into getting into the top 5 (in the India market). We have to grow much more than the market and grow 15-16%,' said M.V. Ramana , Chief Executive Officer, Branded Markets (India and Emerging Markets).'Our large push is to see how the internal growth engine supported by our R&D will grow existing brands, new products and consumer health,' he added.On Friday, the company reported a 22% year-on-year increase in fourth quarter (Jan-Mar) net profit to Rs 1593.90 crore, while revenue for Q4 was Rs 8,506 crore, up 20%.'India for FY25 has grown by 16% so what is critical is in terms of the portfolio we are able to offer in and how do we grow our existing brands, the second is what we have been doing in the past two years that is working with innovative companies to bring in their innovations into the market and what we do see that these innovations are picking pace,' he told ET after the company announced its fourth quarter results.The company attributed the growth to successful product launches, increased revenues from key products in the US and the integration of its acquired Nicotine Replacement Therapy (NRT) business in Europe.For the full year ended March, net profit rose 2% to Rs 5655 crore, while revenue was at Rs 32553.50 crore."We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities,' Co-Chairman & MD G V Prasad said in a press release.Explaining its innovation focus, Ramana said, 'One such opportunity is the product we have launched is toripalimab for nasopharyngeal carcinoma . We see that it is gaining traction and getting good results based on the feedback from doctors.''Two other products we are launching this quarter one of it is a respiratory vaccine for infants. This product has done well globally. Similarly another innovation we are bringing in is a product for allergy the first product approved by CDSCO in this space.''Increasingly the idea is to bring in more assets to India and emerging markets so that the Indian patients and consumers have the same benefits as these innovations in other parts of the world.'The company also looks to expand beyond current offering and is working more on consumer health.Last year, DRL entered a joint venture with FMCG major Nestle in the health and wellbeing space. 'That integrated well and is expected to continue to grow,' said Ramana.On the question of impact of any potential tariffs levied by the US, company officials said there is no clarity at the moment, declining to share an estimate.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

34 minutes ago

• Business Standard

Decision on merger with Biocon Biologics soon, says Siddharth Mittal

We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal Sohini Das Mumbai Listen to This Article Biocon successfully raised ₹4,500 crore through a qualified institutional placement (QIP) last week that saw strong interest from both Indian and global investors. It is also considering a merger of Biocon Biologics with Biocon to tap into business and scientific synergies rather than listing Biocon Biologics. In a virtual interaction with Sohini Das, Siddharth Mittal, chief executive officer (CEO) and managing director (MD) of Biocon outlined his plans. Edited excerpts: Your QIP was successful. What do you plan to do with the proceeds? There was very strong investor demand. The Board had approved raising up to ₹4,500 crore in one,

News18

41 minutes ago

• News18

Stock Market Updates: Sensex Tanks Over 700 Points, Nifty Below 24,950 Mark In Pre-Open

Last Updated: Indian benchmark indices Sensex and Nifty are expected to open on a cautious note today Sensex Today: Indian benchmark indices Sensex and Nifty are expected to open on a cautious note today, as a sharp rise in crude oil prices and escalating geopolitical tensions weigh on investor sentiment. The situation intensified after the United States directly entered the Israel-Iran conflict with strikes on Iranian nuclear facilities, sparking fears of a broader regional war and unsettling global markets. Adding to the pressure, mixed global cues and institutional fund flows are likely to influence market direction in today's session. As of 8:20 AM, GIFT Nifty futures were trading 112 points lower at 25,111, indicating a gap-down start for domestic equities. Global Cues Asia-Pacific markets tumbled on Monday following the US airstrikes on three Iranian nuclear sites, which raised the spectre of a wider conflict in the Middle East and drove oil prices higher. Brent crude rose 2.62% to $79.06 per barrel, while West Texas Intermediate (WTI) gained 2.75% to $75.89 per barrel. Oil prices have been on an upward trend in recent weeks due to rising geopolitical instability in the region. Gold also surged amid the uncertainty, jumping 2.95% to $3,379.60 per ounce as investors flocked to safe-haven assets. In equities, Japan's Nikkei dropped 0.74%, while the broader Topix fell 0.64%. South Korea's Kospi lost 1.22%, and Australia's ASX 200 declined 0.76%. US stock futures retreated during early Asian trading hours. Dow Jones futures were down 0.3%, while S&P 500 and Nasdaq 100 futures slipped 0.3% and 0.4%, respectively. On Wall Street last Friday, two of the three major indices closed in the red. The S&P 500 shed 0.22%, marking its third consecutive loss, and the Nasdaq Composite dropped 0.51%. The Dow Jones Industrial Average, however, inched up by 0.08%. About the Author Aparna Deb Stay updated with all the latest news on the Stock Market, including market trends, Sensex and Nifty updates, top gainers and losers, and expert analysis. Get real-time insights, financial reports, and investment strategies—only on News18. First Published: News business » markets Stock Market Updates: Sensex Tanks Over 700 Points, Nifty Below 24,950 Mark In Pre-Open

Time of India

42 minutes ago

• Time of India

Zen Technologies shares in focus after board approves acquisition of TISA Aerospace

Shares of Zen Technologies are likely to be in focus on Monday, June 23, following the company's announcement of a proposed acquisition of a majority stake in TISA Aerospace, an emerging defence technology firm specialising in loitering munitions and unmanned aerial vehicles (UAVs). In an exchange filing, Zen Technologies disclosed that its Board of Directors, at a meeting held on Saturday, approved an investment of up to Rs 6.56 crore towards the proposed acquisition. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Costco Shoppers Say This Wrinkle Cream Is "Actually Worth It" The Skincare Magazine Undo The investment will be executed through two components: The acquisition of 2,06,518 equity shares of Rs 10 each from an existing shareholder of TISA Aerospace, representing 54.67% of the total equity paid-up share capital of the company. The acquisition of 4,00,000 units of 6% Compulsory Convertible Debentures (CCDs) of Rs 100 face value each, from an existing CCD holder, also issued by TISA. The Board of Directors has unanimously approved the investment, which involves acquiring shares from current stakeholders of TISA as well as CCDs previously issued by TISA. The company stated that the transaction represents an investment in a domain of strategic relevance, comprising indigenously developed defence technologies. Live Events TISA Aerospace is positioned as a domestic player within the high-technology defence ecosystem. The company is engaged in the development of loitering munitions and UAVs—both of which are key segments within the evolving landscape of modern precision-guided weapon systems. Zen Technologies, through this acquisition, is entering a segment associated with advanced defence applications. 'This acquisition is a decisive step towards strengthening Zen's position in the rapidly evolving defence drone sector. TISA's expertise in loitering munitions provides us with immediate access to advanced technologies and platforms that align with the emerging operational requirements of the Armed Forces. TISA has achieved significant R&D milestones, including the successful execution of a project for DRDO with critical design assistance from IIT Madras. By integrating these capabilities with our existing strengths in anti-drone systems and propulsion technologies, we are building a broader and more future-ready defence portfolio,' said Ashok Atluri, Chairman and Managing Director of ZenTechnologies. Also read: How will US strikes on Iran affect Indian markets this week? Shares of Zen Technologies closed flat at Rs 1,900.30 on the BSE on Friday. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)